VisionWave to acquire up to 51% of SaverOne in $7M staged equity exchange

VisionWave Holdings, Inc.

Stage 1: SaverOne issues 19.99% for ~$2.74M in VWAV stock; Milestone 1 triggers another 19.99% (~$2.74M).
Stage 3 adds 11.02% (~$1.51M) after Milestone 2 (defense pilot), giving VWAV ~51% fully diluted.
SaverOne gets non-exclusive worldwide license to VisionWave RF IP for defense/security applications.
Value protection: if VWAV price drops >10% within 10 days, additional shares or warrants issued up to $7M.
SaverOne management may receive up to $3M in VWAV stock grants tied to milestones; VWAV gets board seats.

item 1.01 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001731122-26-000117
form_type: 8-K
ticker: VWAV
cik: 0002038439
company_name: VisionWave Holdings, Inc.
filed_at: 2026-01-26T23:59:59+00:00
discovered_at: 2026-05-14T18:02:37.091948+00:00
generated_at: 2026-05-16T08:08:52.660271+00:00
sec_items: ["1.01", "7.01", "9.01"]
event_type: m_and_a
sentiment: neutral
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001731122-26-000117
json_url: https://secwatch.observer/filing/0001731122-26-000117.json
markdown_url: https://secwatch.observer/filing/0001731122-26-000117.md
text_url: https://secwatch.observer/filing/0001731122-26-000117.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/2038439/000173112226000117/0001731122-26-000117-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/2038439/000173112226000117/e7252_8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001731122-26-000117

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.